This article was originally published on NisonCo and appears here with permission. Mainstream dialogue around teenagers and cannabis is callous ... Read More
A cannabis industry consultant who sharply criticized the Sioux Falls City Council’s process for how they regulated medical marijuana licensing ... Read More
BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, ... Read More
Simply put, the memo implies that anyone likely to continue using cannabis and other illegal drugs has no business applying for a security clearance. Also, workers found in the future using illicit drugs might have their security clearance revoked. This policy is not limited to psychoactive drugs alone. It also extends to CBD products derived from hemp plants. Although the U.S. Congress legalized the consumption of hemp products as long as they contain less than 0.3% THC, the national intelligence agency maintains that most of these products contain more than 0.3% THC. Rather than take chances, all workers are expected to stay away from all forms of cannabis and hemp.
A federal judge in New Jersey has ruled that claims in two Horizon Pharma patents that cover the arthritis drug Vimovo never should have been issued in the first place, sinking an infringement suit against Dr. Reddy's Laboratories that had been rattling around for half a decade.
A Virginia federal court has sided with buyers in their bid to limit the scope of competition considered in their suit accusing Merck and Glenmark of striking a deal to keep generic versions of cholesterol drug Zetia off the market.
The firm Flora Growth divulged its intention to seek Emergency Use Authorization for a cannabis-based product under the COVID-19 protocols in force in Columbia. Suppose the firm does get the necessary approval. In that case, it will be the first covid-19 prevention product in Columbia based on the cannabis herb. The firm has applied for […]
TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company ... Read More